Advertisement
Advertisement

SMMT

SMMT logo

Summit Therapeutics Inc. Common Stock

14.97
USD
Sponsored
+1.13
+8.12%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

14.97

0.00
0.00%

SMMT Earnings Reports

Positive Surprise Ratio

SMMT beat 3 of 13 last estimates.

23%

Next Report

Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$92.73M
/
-$0.07
Implied change from Q3 25 (Revenue/ EPS)
--
/
-77.42%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-12.50%

Summit Therapeutics Inc. Common Stock earnings per share and revenue

On Oct 20, 2025, SMMT reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.13 USD, resulting in a -130.48% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 92.73 million USD, implying an decrease of -77.42% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Summit Therapeutics Inc. Common Stock reported EPS of -$0.31, missing estimates by -130.48%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.55%, changed from $20.99 before the earnings release to $20.04 the day after.
The next earning report is scheduled for Feb 23, 2026.
Based on 19 analysts, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $92.73M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement